StreetInsider.com News Articles

Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'

Mon, 24 Aug 2026 05:07:34 -0400

(Updated - August 24, 2026 5:07 AM EDT)

Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (NASDAQ: JANX) from Peerperform to Outperform with a price target of $23.00.

The analyst comments "JANX stock underperformed the XBI over the past 12 mo (-24% vs. +86%); we think the autoimmune data in 4Q could change the trajectory. Our analysis suggests potent B cell depletion + low CRS is feasible for JANX011. At $150M EV, risk/reward looks favorable; upgrade to OP. Janux’s ARM concept is differentiated. Most autoimmune TCEs recruit the entire CD3+ T cell pool but try to control cytokines through weak CD3 affinity,

Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'

Mon, 24 Aug 2026 05:07:34 -0400

(Updated - August 24, 2026 5:07 AM EDT)

Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (NASDAQ: JANX) from Peerperform to Outperform with a price target of $23.00.

Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'

Mon, 24 Aug 2026 05:07:34 -0400

(Updated - August 24, 2026 5:07 AM EDT)

Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (NASDAQ: JANX) from Peerperform to Outperform with a price target of $23.00.

Wolfe Research Upgrades Janux Therapeutics (JANX) to Outperform, 'An ARM Out of the Penalty Box'

Mon, 24 Aug 2026 05:07:34 -0400

(Updated - August 24, 2026 5:07 AM EDT)

Wolfe Research analyst Kalpit Patel upgraded Janux Therapeutics (NASDAQ: JANX) from Peerperform to Outperform with a price target of $23.00.

TD Cowen Assumes Janux Therapeutics (JANX) at Buy

Sat, 22 Aug 2026 07:54:43 -0400

TD Cowen analyst Tara Bancroft assumes coverage on Janux Therapeutics (NASDAQ: JANX) with a Buy rating.

For an analyst ratings summary and ratings history on Janux Therapeutics click here. For more ratings news on Janux Therapeutics click here.

Shares of Janux Therapeutics closed at $17.39 yesterday.

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930550.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930550.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260813/26919219.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: Janus Henderson Group Ltd.

Thu, 13 Aug 2026 12:42:00 -0400

si-local-file:///var/storage/secattach/20260813/26919219.html

Janux Therapeutics (JANX) PT Lowered to $35 at Stifel

Fri, 07 Aug 2026 10:28:13 -0400

Stifel analyst Stephen Willey lowered the price target on Janux Therapeutics (NASDAQ: JANX) to $35.00 (from $38.00) while maintaining a Buy rating.

Janux Therapeutics, Inc. (JANX) Misses Q2 EPS by 8c

Thu, 06 Aug 2026 18:09:00 -0400

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q2 EPS of ($0.35), $0.08 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $10.27 million versus the consensus estimate of $17.94 million.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

Form 10-Q Janux Therapeutics, Inc. For: Jun 30

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884374.html

Form 10-Q Janux Therapeutics, Inc. For: Jun 30

Thu, 06 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260806/26884374.html

Form 8-K Janux Therapeutics, Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883863.html

Form 8-K Janux Therapeutics, Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883863.html

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:02:00 -0400

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)
JANX011 Phase 1 healthy volunteer study progressing as planned
JANX013 remains on track for clinical initiation in the second half of 2026
Strong balance sheet supports advancement of multiple clinical programs with $970.9 million in cash, cash equivalents and short-term investments at end of 2Q26

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026,

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:02:00 -0400

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)
JANX011 Phase 1 healthy volunteer study progressing as planned
JANX013 remains on track for clinical initiation in the second half of 2026
Strong balance sheet supports advancement of multiple clinical programs with $970.9 million in cash, cash equivalents and short-term investments at end of 2Q26

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:02:00 -0400

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)
JANX011 Phase 1 healthy volunteer study progressing as planned
JANX013 remains on track for clinical initiation in the second half of 2026
Strong balance sheet supports advancement of multiple clinical programs with $970.9 million in cash, cash equivalents and short-term investments at end of 2Q26

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Thu, 06 Aug 2026 16:02:00 -0400

JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts
JANX014 Phase 1 study continues enrolling patients with metastatic castration-resistant prostate cancer (mCRPC)
JANX011 Phase 1 healthy volunteer study progressing as planned
JANX013 remains on track for clinical initiation in the second half of 2026
Strong balance sheet supports advancement of multiple clinical programs with $970.9 million in cash, cash equivalents and short-term investments at end of 2Q26

Form 4 Janux Therapeutics, Inc. For: Jul 31 Filed by: Campbell David Alan

Fri, 31 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26851933.html

Form 4 Janux Therapeutics, Inc. For: Jul 31 Filed by: Campbell David Alan

Fri, 31 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260731/26851933.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: BlackRock, Inc.

Tue, 28 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260728/26827978.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: BlackRock, Inc.

Tue, 28 Jul 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260728/26827978.html

Form 4 Janux Therapeutics, Inc. For: Jul 08 Filed by: Campbell David Alan

Fri, 10 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758282.html

Form 4 Janux Therapeutics, Inc. For: Jul 08 Filed by: Campbell David Alan

Fri, 10 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26758282.html